The crucial role of high-fidelity spent media analytics in AI-driven biopharmaceutical R&D and production

Ferdi van Dorsten, PhD, Team Lead Spent Media Analysis, Ferdi.VanDorsten@bpt.eurofinseu.com; Jochem Rutters, PhD, Business Unit Manager, Jochem.Rutters@bpt.eurofinseu.com; Eurofins Spinnovation Analytical B.V. (part of Eurofins BioPharma Product Testing, The Netherlands)

As the biopharmaceutical industry enters the BioPharma 4.0 era, driven by the integration of Artificial Intelligence (AI) and Machine Learning (ML), the foundation of successful AI integration lies in the quality of the data used to train and validate predictive models. Eurofins Spinnovation Analytical B.V. stands at the forefront of this evolution by providing high-quality Spent Media Analysis (SMA) through its proprietary SPEDIA™ platform, an analytical service designed to deliver precise, reproducible metabolic insights essential for AI-driven bioprocess optimisation.

Our SPEDIA™ platform combines three advanced analytical technologies: Nuclear Magnetic Resonance Spectroscopy (NMR), Liquid Chromatography-Mass Spectrometry (LC-MS), and Inductively Coupled Plasma-Optical Emission Spectroscopy (ICP-OES). This unique combination ensures high precision in quantitative metabolite profiling, covering a broad range of culture media components, including amino acids, sugars, organic acids, vitamins, polyamines, buffers, surfactants, and trace elements. The result is a comprehensive, structured, and quantitative dataset that empowers clients to develop robust AI models for cell culture prediction, real-time process control, and automated quality assurance.

The importance of high-quality analytical data for AI and regulatory compliance

AI applications in biopharmaceutical production demand data that is accurate, reproducible, and compliant with regulatory standards. Eurofins Spinnovation Analytical’s SMA service delivers:

• Enhanced Predictive Accuracy: AI models (like digital twins) trained on high-fidelity data yield more reliable insights into cell growth and metabolite consumption.
• Improved Process Control: Better process understanding through SMA, and digital twins help prevent deviations before they impact production.
• Batch-to-Batch Consistency: Reliable quality control of raw material composition detects and reduces variability, improving reproducibility.
• Regulatory Confidence: Structured, validated data simplifies compliance with global GMP standards.
• Cost Efficiency: Better process understanding leads to reduced production costs and increased yields.

Eurofins Spinnovation Analytical’s commitment to data integrity and standardisation also addresses key challenges in AI-enabled biopharma, including scalability, data security, and platform compatibility. By providing high-fidelity SMA data, Eurofins Spinnovation Analytical enables clients to develop AI models that optimise bioprocesses in real time, predict cell culture dynamics, ensure batch consistency, and automate quality control for enhanced efficiency and reliability in biopharmaceutical production.

As AI continues to reshape biopharmaceutical R&D and production, the need for reliable, high-quality SMA data has never been more prominent. Eurofins Spinnovation Analytical’s SMA service empowers biopharma, biotech, and CDMO companies to fully leverage AI in their development processes. The SPEDIA™ platform provides clients with essential metabolic insights that accelerate decision-making, streamline development, and enhance production efficiency.

For more information, visit: www.eurofins.nl/en/biopharma-product-testing-nl/services/facility-and-process-control/spent-media-analysis/ or contact us at: info.EBPT-NL@bpt.eurofinseu.com